This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raaijmakers, M. H.G.P. Articles by Raymakers, R. A.P. Search for Related Content PubMed PubMed Citation Articles by Raaijmakers, M. H.G.P. Articles by Raymakers, R. A.P.

Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38– Cells in Acute Myeloid Leukemia

¹ Department of Hematology and ² Central Hematology Laboratory, University Medical Center Nijmegen, St. Radboud, Nijmegen, the Netherlands; and ³ Department of Pathology, Free University, Amsterdam, the Netherlands

Requests for reprints: Marc H.G.P. Raaijmakers, Department of Hematology, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. Phone: 31-24-3614762; Fax: 31-24-3542080; E-mail: h.raaijmakers{at}chl.umcn.nl.

Purpose: Acute myeloid leukemia (AML) is considered a stem cell disease. Incomplete chemotherapeutic eradication of leukemic CD34+38– stem cells is likely to result in disease relapse. The purpose of this study was to investigate the role of the breast cancer resistance protein (BCRP/ATP-binding cassette, subfamily G, member 2) in drug resistance of leukemic stem cells and the effect of its modulation on stem cell eradication in AML.

Experimental Design: BCRP expression (measured flow-cytometrically using the BXP21 monoclonal antibody) and the effect of its modulation (using the novel fumitremorgin C analogue KO143) on intracellular mitoxantrone accumulation and in vitro chemosensitivity were assessed in leukemic CD34+38– cells.

Results: BCRP was preferentially expressed in leukemic CD34+38– cells and blockage of BCRP-mediated drug extrusion by the novel fumitremorgin C analogue KO143 resulted in increased intracellular mitoxantrone accumulation in these cells in the majority of patients. This increase, however, was much lower than in the mitoxantrone-resistant breast cancer cell line MCF7-MR and significant drug extrusion occurred in the presence of BCRP blockage due to the presence of additional drug transport mechanisms, among which ABCB1 and multiple drug resistance protein. In line with these findings, selective blockage of BCRP by KO143 did not enhance in vitro chemosensitivity of leukemic CD34+38– cells.

Conclusions: These results show that drug extrusion from leukemic stem cells is mediated by the promiscuous action of BCRP and additional transporters. Broad-spectrum inhibition, rather than modulation of single mechanisms, is therefore likely to be required to circumvent drug resistance and eradicate leukemic stem cells in AML.

Key Words: Leukemias and lymphomas • Stem Cell Biology • Drug Resistance

This article has been cited by other articles:

				M. L. Guzman, X. Li, C. A. Corbett, R. M. Rossi, T. Bushnell, J. L. Liesveld, J. Hebert, F. Young, and C. T. Jordan Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8) Blood, December 15, 2007; 110(13): 4436 - 4444. [Abstract] [Full Text] [PDF]

				M. H.G.P. Raaijmakers, E. P.L.M. de Grouw, B. A. van der Reijden, T. J.M. de Witte, J. H. Jansen, and R. A.P. Raymakers ABCB1 Modulation Does Not Circumvent Drug Extrusion from Primitive Leukemic Progenitor Cells and May Preferentially Target Residual Normal Cells in Acute Myelogenous Leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3452 - 3458. [Abstract] [Full Text] [PDF]

				J. A.F. Marteijn, L. van Emst, C. A.J. Erpelinck-Verschueren, G. Nikoloski, A. Menke, T. de Witte, B. Lowenberg, J. H. Jansen, and B. A. van der Reijden The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells Blood, December 15, 2005; 106(13): 4114 - 4123. [Abstract] [Full Text] [PDF]